OBIO Member: CCAB Signs Agreement with Pionyr Immunotherapeutics Inc.

Ontario Industry Updates
Written By obio

OBIO Member, CCAB, has signed a collaboration and license agreement with Pionyr Immunotherapeutics Inc. to discover antibody drug development candidates.  Through the University of Toronto, CCAB, has granted a non-exclusive license to Pionyr Immunotherapeutics encompassing an undisclosed number of antibody programs in Pionyr’s therapeutic pipeline.

Click HERE for the Full Press Release

obio
Previous

CAAP Companies: Eve Medical & QoC Health in The Globe and Mail
Next

OBIO Member: Steadiwear Wins RESI on MaRS Innovation Challenge